Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. [electronic resource]
Producer: 20130411Description: 1138-44 p. digitalISSN:- 1365-2133
- Adult
- Aged
- Benzamides
- Double-Blind Method
- Female
- Fibrosis -- drug therapy
- Humans
- Imatinib Mesylate
- Male
- Middle Aged
- Piperazines -- therapeutic use
- Platelet-Derived Growth Factor -- metabolism
- Protein Kinase Inhibitors -- therapeutic use
- Pyrimidines -- therapeutic use
- Quality of Life
- Scleroderma, Diffuse -- drug therapy
- Skin -- pathology
- Transforming Growth Factor beta -- metabolism
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.